Statute Details
- Title: Health Products (Composition of Offences) Regulations 2011
- Act Code: HPA2007-S542-2011
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D), specifically section 72
- Commencement: 3 October 2011
- Status: Current version as at 27 March 2026
- Key Provisions: Regulation 1 (citation and commencement); Regulation 2 (compoundable offences); Regulation 3 (deletion of a related provision)
- Compounding Authority: Chief Executive of the Health Sciences Authority (HSA) or an authorised officer, under section 65 of the Health Products Act
- Notable Amendments in the Extract: S 540/2016 (w.e.f. 1 Nov 2016); S 150/2021 (w.e.f. 8 Mar 2021); S 832/2023 (w.e.f. 18 Dec 2023)
What Is This Legislation About?
The Health Products (Composition of Offences) Regulations 2011 (“Composition Regulations”) is a Singapore subsidiary law that identifies which offences under the Health Products Act and its related regulations may be “compounded”. In practical terms, compounding is an administrative alternative to prosecution: instead of going to court, an eligible person may pay a composition sum (subject to the statutory scheme) to resolve certain regulatory breaches.
The Regulations do not create new offences in themselves. Rather, they operate as a procedural and enforcement tool. They “select” categories of offences that the Chief Executive of the Health Sciences Authority (or an authorised officer) may compound under section 65 of the Health Products Act. This helps the regulator manage compliance issues efficiently—especially where breaches are technical, isolated, or otherwise suitable for administrative resolution.
Because the Regulations are periodically amended to add offences from newer regulatory regimes (for example, active ingredients, medical devices, therapeutic products, clinical trials, and other specialised categories), the scope of compoundable conduct evolves with the broader Health Products regulatory framework.
What Are the Key Provisions?
Regulation 1 (Citation and commencement) confirms the legal identity and effective date of the Regulations. It provides that the Regulations may be cited as the Health Products (Composition of Offences) Regulations 2011 and came into operation on 3 October 2011. For practitioners, this matters when assessing whether a particular alleged breach falls within the compounding framework at the relevant time.
Regulation 2 (Compoundable offences) is the core provision. It lists offences that “may be compounded” in accordance with section 65 of the Health Products Act. The compounding power is vested in the Chief Executive or an officer of the Authority authorised in writing by the Chief Executive. This wording is important: it clarifies that compounding is not automatic; it is a discretionary enforcement mechanism exercised by the regulator (or a properly authorised delegate).
Regulation 2 is drafted in a structured way. It first captures a range of offences under the Health Products Act itself (for example, offences under specified subsections of sections 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 35, 36, 40, 41, 42, 43, 44, 49, 50, and 66(4)). The effect is that certain statutory breaches—identified by reference to particular sections and subsections—are within the compounding regime.
It then expands to offences under various subsidiary regulations made under the Health Products Act. The extract shows compoundable offences across multiple domains, including:
- Active ingredients: offences under section 47(4) of the Act relating to contraventions of the Health Products (Active Ingredients) Regulations 2023, except offences relating to contraventions of regulations 4 or 5 of those Regulations (added by S 832/2023 w.e.f. 18/12/2023).
- Cosmetic products: offences under specified provisions of the Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (regulation 4(3), 10(3), 11(4)(a)).
- Medical devices: offences under specified provisions of the Health Products (Medical Devices) Regulations 2010 (including offences under regulation 13A(3), 31(5), 32(2), 36A(5), 37, 38(3), 39(3), 39A(3), 39B(3), 40(2), 41(3), 43(2), 44(4), 45(3), 46(4), 47(3), 48(6) or (7)(b), and 49(5) or (6)(b)).
- Therapeutic products: offences under specified provisions of the Health Products (Therapeutic Products) Regulations 2016 (including regulation 21(4), 31(3), 32(4), 33(3), 40, 41(6) or (7)(b), 42(4) or (5)(b), 43(2), 44(3), 45(2), 46(8), 48(7) or 65(3)).
- Retail pharmacies: an offence under regulation 7(5) of the Health Products (Licensing of Retail Pharmacies) Regulations 2016.
- Advertisement rules: an offence under regulation 15(2) of the Health Products (Advertisement of Therapeutic Products) Regulations 2016, renamed as the Health Products (Advertisement of Specified Health Products) Regulations 2016 from 1 March 2021 (as reflected by the amendment history).
- Clinical trials: offences under regulation 29(1)(a) of the Health Products (Clinical Trials) Regulations 2016, but only in respect of a defined set of contraventions across many regulations (regulation 4(4) or (6), 5(1)–(6), 6, 7(2), 8(1), 9(1), 10(1), (2), (4) or (6), 11(1)–(3), 12(1)–(4), 13(1)–(2), 14, 15, 16(1) or (9), 17(3), (4) or (5), 18(1), 19(3), 22(2), 23(1) or (3), 23A(1), (3) or (4), 24(1), (2) or (4), 25(1)–(4), or 26(1)–(4)).
- Clinical research materials: an offence under regulation 24(1)(a) of the Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016, renamed as the Health Products (Clinical Research Materials) Regulations 2016 from 1 March 2021.
- Oral dental gums: offences under specified provisions of the Health Products (Oral Dental Gums) Regulations 2016.
- Cell, tissue and gene therapy products: offences under specified provisions of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021.
Regulation 3 (Amendment of Health Products (Medical Devices) Regulations 2010) deletes regulation 51 of the Health Products (Medical Devices) Regulations 2010. This is a technical but significant housekeeping amendment. It suggests that the earlier medical devices compounding provision was superseded or consolidated by the 2011 Composition Regulations. For practitioners, this deletion means that any reliance on the former regulation 51 should be carefully checked against the current legal framework.
How Is This Legislation Structured?
The Regulations are short and structured around three provisions. Regulation 1 is administrative (citation and commencement). Regulation 2 is the substantive list of offences that may be compounded, drafted by cross-referencing specific sections and regulations across the Health Products Act and multiple subsidiary regulations. Regulation 3 performs a targeted amendment by deleting a specific provision in the medical devices regulations. Overall, the structure reflects a “catalogue” model: the Regulations function as a reference list for compounding eligibility rather than a comprehensive compliance code.
Who Does This Legislation Apply To?
The compounding regime applies to persons who are alleged to have committed offences within the scope of the listed provisions. In the Health Products context, this typically includes regulated entities and individuals involved in the manufacture, importation, distribution, licensing, advertising, and clinical research activities relating to health products (including medical devices, therapeutic products, cosmetics, active ingredients, and specialised categories such as cell/tissue/gene therapy products).
However, the Regulations themselves do not impose direct compliance obligations; they govern how certain offences may be dealt with. The practical effect is that, where an offence falls within Regulation 2, the HSA’s Chief Executive (or authorised officer) may offer compounding under section 65 of the Health Products Act. Whether compounding is offered—and on what terms—depends on the statutory compounding process and the regulator’s discretion.
Why Is This Legislation Important?
For practitioners, the key value of the Composition Regulations lies in enforcement strategy and risk management. Knowing whether an alleged offence is “compoundable” can materially affect advice to clients on next steps—such as whether to engage early with the regulator, how to frame submissions, and how to assess the likelihood of avoiding prosecution.
Because Regulation 2 is drafted with detailed cross-references, it also supports precise legal triage. A lawyer can compare the alleged conduct to the relevant offence provision and determine whether it falls within the compoundable list. This is particularly important in complex health product regulatory matters where multiple regimes may apply (e.g., a medical device that is also advertised as a specified health product, or a clinical trial involving therapeutic products and associated materials).
Finally, the amendment history demonstrates that the compounding catalogue is updated as new regulatory instruments are introduced. The addition of active ingredients contraventions in 2023 and the expansion across therapeutic, clinical trial, and advanced therapy product regulations reflect the regulator’s continuing effort to provide an administrative pathway for enforcement across the evolving Health Products ecosystem. Practitioners should therefore always confirm the current version (as at the relevant date) and check whether amendments have broadened or narrowed compounding eligibility.
Related Legislation
- Health Products Act (Cap. 122D) — in particular, section 65 (compounding) and section 72 (making of regulations)
- Health Products (Medical Devices) Regulations 2010 (G.N. No. S 436/2010)
- Health Products (Active Ingredients) Regulations 2023 (G.N. No. S 831/2023)
- Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (G.N. No. S 683/2007)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016)
- Health Products (Advertisement of Therapeutic Products) Regulations 2016 (renamed as from 1 March 2021)
- Health Products (Clinical Trials) Regulations 2016 (G.N. No. S 331/2016)
- Health Products (Clinical Research Materials) Regulations 2016 (renamed as from 1 March 2021)
- Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
Source Documents
This article provides an overview of the Health Products (Composition of Offences) Regulations 2011 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.